1. Economic evaluation of culprit lesion only PCI vs. immediate multivessel PCI in acute myocardial infarction complicated by cardiogenic shock: the CULPRIT-SHOCK trial
- Author
-
Uwe Zeymer, Jose Antonio Robles-Zurita, Holger Thiele, Andrew Briggs, Zahidul Quayyum, Suzanne de Waha-Thiele, Keith G. Oldroyd, Steffen Desch, and Dikshyanta Rana
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Cost-Benefit Analysis ,Economics, Econometrics and Finance (miscellaneous) ,Myocardial Infarction ,Shock, Cardiogenic ,Coronary Artery Disease ,030204 cardiovascular system & hematology ,Culprit-shock trial ,Culprit ,State Medicine ,Coronary artery disease ,03 medical and health sciences ,0302 clinical medicine ,Percutaneous Coronary Intervention ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,Myocardial infarction ,cardiovascular diseases ,I10 ,health care economics and organizations ,Aged ,Original Paper ,business.industry ,Health Policy ,Percutaneous coronary intervention ,Cost-effectiveness analysis ,Middle Aged ,medicine.disease ,Economic evaluation ,Quality-adjusted life year ,Treatment Outcome ,Pre-trial model ,Conventional PCI ,Cardiology ,Decision analytic modelling ,Female ,business ,Incremental cost-effectiveness ratio - Abstract
Background The CULPRIT-SHOCK trial compared two treatment strategies for patients with acute myocardial infarction and multivessel coronary artery disease complicated by cardiogenic shock: (a) culprit vessel only percutaneous coronary intervention (CO-PCI), with additional staged revascularisation if indicated, and (b) immediate multivessel PCI (MV-PCI). Methods A German societal and national health service perspective was considered for three different analyses. The cost utility analysis (CUA) estimated costs and quality adjusted life years (QALYs) based on a pre-trial decision analytic model taking a lifelong time horizon. In addition, a within trial CUA estimated QALYs and costs for 1 year. Finally, the cost effectiveness analysis (CEA) used the composite primary outcome, mortality and renal failure at 30-day follow-up, and the within trial costs. Econometric and survival analysis on the trial data was used for the estimation of the model parameters. Subgroup analysis was performed following an economic protocol. Results The lifelong CUA showed an incremental cost effectiveness ratio (ICER), CO-PCI vs. MV-PCI, of €7010 per QALY and a probability of CO-PCI being the most cost-effective strategy > 64% at a €30,000 threshold. The ICER for the within trial CUA was €14,600 and the incremental cost per case of death/renal failure avoided at 30-day follow-up was €9010. Cost-effectiveness improved with patient age and for those without diabetes. Conclusions The estimates of cost-effectiveness for CO-PCI vs. MV-PCI have been shown to change depending on the time horizon and type of economic evaluation performed. The results favoured a long-term horizon analysis for avoiding underestimation of QALY gains from the CO-PCI arm.
- Published
- 2020